GHRH and non-small cell lung carcinoma: In summary, our study demonstrates that MIA-class GHRH antagonists enhance the sensitivity of human NSCLC cell lines and primary NSCLC cells to the antitumor effects of IR while suppressing molecular pathways associated with radioresistance.